A GUIDING LIGHT IN EARLY DISEASE DETECTION
IMMUNOFLUORESCENCE
Sensitive detection of multiple biological targets simultaneously.
Luminspheres™ being several orders of magnitude brighter than molecular fluorophores and multicolours fluorescing simultaneously permits direct concurrent immunofluorescent staining and imaging of multiple biological targets in a single sample.
DRACS
Digital Rapid Autonomous Cancer Screening (DRACS™) is revolutionising the early detection of cancer from a liquid biopsy.
Luminspheres™ stained Circulating Tumour Cells (CTCs) present in a blood sample are detected by high-throughput digital analysis and counted by software that supports diagnosis.
HER2 ULTRA-LOW DETECTION
Ultra-sensitive IHC HER2 detection identifies breast cancer patients that could benefit antibody-drug conjugate therapy.
Luminspheres™ extraordinary brightness can detect ultra-low levels of HER2 present in tissue graded HER2-0. A high-throughput digital scanner images any Luminspheres™ stained HER2 present and software stratifies HER2-ultralow and HER2-null to support diagnosis and treatment selection.
CRISPR
CRISPR powered detection that enables rapid point of care genomic testing.
The presence of target RNA results in a concomitant increase in bright green Luminspheres Reporter signal that can be detected quantitatively in a laboratory setting or at point of care by lateral flow.